HHS issues temporary policy permitting compounding pharmacies to produce certain peptide drugs

The U.S. Department of Health and Human Services announced a new policy that temporarily authorizes compounding pharmacies to manufacture specific peptide products that are not otherwise commercially available.

The measure is aimed at easing drug shortages and improving patient access while the FDA continues its review of peptide manufacturing standards.

The temporary authorization covers a defined list of peptides and includes reporting requirements to maintain safety and traceability.

Industry observers say the policy may provide short‑term relief for patients, but it does not replace the need for full FDA approval of these drugs.